Amgen's (AMGN) OTEZLA Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Amgen's (AMGN) OTEZLA Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis

OTEZLA® (apremilast) Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis

April 23, 2021 4:00 PM EDT

THOUSAND OAKS, Calif., April 23, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced Otezla® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease, according to findings from the placebo-controlled, Phase 3 ADVANCE trial. Results were presented at the American Academy of Dermatology Virtual Meeting Experience 2021. 

"Many people with mild-to-moderate plaque psoriasis still report challenges in managing their symptoms, which can have a significant impact on their daily lives, despite the availability of existing topical treatment options," said Linda... More